Sign up to save your podcasts
Or
Share Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer.
CME information and select publications here.
View all episodes
By Dr. Neil Love
4.4
3030 ratings
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer.
CME information and select publications here.
More shows like Lung Cancer Update
View all
NEJM This Week
319 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Breast Cancer Update
67 Listeners
Hematologic Oncology Update
75 Listeners
Prostate Cancer Update
14 Listeners
Gastrointestinal Cancer Update
17 Listeners
Gynecologic Oncology Update
13 Listeners
Dermatologic Oncology Update
0 Listeners
Lung Cancer CancerCare Connect Education Workshops
7 Listeners
Research To Practice | Oncology Videos
118 Listeners
ASCO Daily News
57 Listeners
The Long Run with Luke Timmerman
124 Listeners
ASCO Guidelines
44 Listeners
Lung Cancer Considered
27 Listeners
Oncology Today with Dr Neil Love
58 Listeners
Business Of Biotech
86 Listeners
Two Onc Docs
189 Listeners